Business Wire

Q3 FY2024

14.3% Year on Year Revenue Decrease to £174.4 million

11.8% Revenue Decrease at Constant Currency

Diluted EPS £(0.03) compared to £0.42 in the prior year comparative period

Adjusted diluted EPS £0.22 compared to £0.59 in the prior year comparative period

LONDON--(BUSINESS WIRE)-- Endava plc (NYSE: DAVA) ("Endava" or the "Company"), a leading technology services company combining world-class engineering, industry expertise and a... (continue reading...)

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock.

The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health’s blood test to screen for colorectal cancer in... (continue reading...)

CHICAGO--(BUSINESS WIRE)-- HDI Global Insurance Company, the US subsidiary of international commercial insurer, HDI Global SE (HDI) is pleased to announce its strategic partnership with Hallmark Financial Services, Inc. (“Hallmark”) to provide capacity and product development support for its General Aviation and Small to Medium Sized Commercial property and casualty insurance products effective June 1, 2024.

This press release features multimedia. View the full... (continue reading...)

Free, educational session will focus on non-financial aspects of retirement planning

DAYTON, Ohio--(BUSINESS WIRE)-- Retirement planning goes beyond ensuring financial stability. It encompasses non-financial aspects essential for achieving a fulfilling and meaningful retirement. To address this need for more comprehensive retirement planning, Buckingham Advisors is on June 6, 2024 hosting a retirement readiness session titled, “A Meaningful Retirement: Beyond... (continue reading...)

Financing includes participation from new and existing investors

Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027

Supports ongoing advancement of pipeline with multiple clinical-stage precision-guided therapeutics

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and... (continue reading...)